Anirban Maitra, Scientific Director of Sheikh Ahmed Center for Pancreatic Cancer Research and Professor of Pathology and Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center, shared a post on X about a paper by Zev A. Wainberg et al. published in the Nature Medicine:
“The final results from Elicio Therapeutics AMPLIFY trial are in Nature Medicine reinforcing what has been seen with other platforms – a robust T cell response to tumor antigens post-vaccine is associated with delayed Pancreatic Cancer recurrence after surgery.”
Title: Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results
Authors: Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon M. Kasi, Craig E. Devoe, Alexis D. Leal, Vincent Chung, James R. Perry, Thian Kheoh, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Shubham Pant, Eileen M. O’Reilly
You can read the Full Article in the Nature Medicine.
More posts featuring Anirban Maitra on OncoDaily.
